Cutaneous and Mucosal Aphthosis during Temsirolimus Therapy for Advanced Renal Cell Carcinoma: Review of Cutaneous and Mucosal Side Effects of mTOR Inhibitors

A. de Masson,N. Fouchard,L. Mery-Bossard,J.-N. Dauendorffer

Cutaneous and Mucosal Aphthosis during Temsirolimus Therapy for Advanced Renal Cell Carcinoma: Review of Cutaneous and Mucosal Side Effects of mTOR Inhibitors

2011

A. de Masson
N. Fouchard
L. Mery-Bossard
J.-N. Dauendorffer

Temsirolimus, an inhibitor of the mammalian target of rapamycin (mTOR), is a new targeted therapy used in advanced renal cell carcinoma and mantle cell lymphoma and is currently tested in several othe

Keywords:

Discovery and development of mTOR inhibitors
Targeted therapy
PI3K/AKT/mTOR pathway
Mantle cell lymphoma
Temsirolimus
Pathology
Immunology
Renal cell carcinoma
Medicine
Concomitant
Sirolimus
Stomatitis

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations